SCHEMBL2028671

SCHEMBL2028671

O=C(Nc1ccccc1C(=O)O)c1ccc(C(=O)Nc2ccccc2C(=O)O)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.86
MEN1 O00255 4/20 0.77
KMT2A Q03164 4/20 0.77
PKM P14618 2/20 0.77
KCNK2 O95069 1/20 0.71
KCNK10 P57789 1/20 0.71
NPC1 O15118 2/20 0.69
RAB9A P51151 2/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65
CA4 P22748 1/20 0.65
CA7 P43166 1/20 0.65
CHEK1 O14757 1/20 0.65
PIM1 P11309 1/20 0.65
MAPK8 P45983 1/20 0.65
CLK4 Q9HAZ1 1/20 0.65
PDCD1 Q15116 1/20 0.65
CD274 Q9NZQ7 1/20 0.65
MAPT P10636 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12700422 0.96 DHODH (0.81) DHODHMEN1KMT2APKMKCNK2
SCHEMBL414754 0.96 MEN1 (0.83) DHODHMEN1KMT2APKMKCNK2
SCHEMBL31053873 0.96 MEN1 (0.83) DHODHMEN1KMT2APKMKCNK2
SCHEMBL16404480 0.94 DHODH (0.78) DHODHMEN1KMT2APKMKCNK2
SCHEMBL4670044 0.94 DHODH (0.78) DHODHMEN1KMT2APKMKCNK2
SCHEMBL8439303 0.94 MEN1 (0.80) DHODHMEN1KMT2APKMKCNK2
SCHEMBL5931215 0.93 DHODH (0.76) DHODHMEN1KMT2APKMKCNK2
SCHEMBL14075233 0.93 DHODH (1.00) DHODHMEN1KMT2APKMKCNK2
SCHEMBL15183709 0.92 KMT2A (0.77) DHODHMEN1KMT2APKMKCNK2
SCHEMBL14855554 0.92 KMT2A (0.77) DHODHMEN1KMT2APKMKCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2332528-A1 Substituted aromatic dicarbonic acid amides as medicaments Grünenthal GmbH (DE) 2011-06-15 EP claimed
WO-1995017321-A1 AIRBAG CONTAINING LIQUID CRYSTALLINE POLYMER BLEND AKZO NOBEL N.V. (NL) 1995-06-29 WO claimed
WO-1994011417-A1 THERMOTROPIC LIQUID CRYSTALLINE POLYAMIDE AKZO NOBEL INC. (US) 1994-05-26 WO claimed
US-5286838-A Copolymer of thermoplastic aliphatic polyamide and mesogen with ortho-and/or meta-linked aromatic groups AKZO N.V. (NL) 1994-02-15 US claimed
EP-3056488-A1 BISBENZOXAZINONE COMPOUND Teijin Chemicals, Ltd. (JP) 2016-08-17 EP disclosed
EP-2505585-B1 BIS-BENZOXAZINONE COMPOUND TEIJIN CHEMICALS LTD (JP) 2016-08-03 EP disclosed
US-20120252941-A1 BISBENZOXAZINONE COMPOUND TEIJIN CHEMICALS, LTD. (JP) 2012-10-04 US disclosed
EP-2332528-A1 Substituted aromatic dicarbonic acid amides as medicaments Grünenthal GmbH (DE) 2011-06-15 EP disclosed
WO-1994011417-A1 THERMOTROPIC LIQUID CRYSTALLINE POLYAMIDE AKZO NOBEL INC. (US) 1994-05-26 WO disclosed
US-5286838-A Copolymer of thermoplastic aliphatic polyamide and mesogen with ortho-and/or meta-linked aromatic groups AKZO N.V. (NL) 1994-02-15 US disclosed
EP-0383941-B1 ULTRAVIOLET ABSORBING COSMETIC TEIJIN LTD (JP) 1993-11-03 EP disclosed
US-5234681-A A phenylene-, naphthylene- or biphenylenebis(3,1-benzoxazin-4-one; sunscreen agents; colorless, odorless and nonirritating; durability TEIJIN LIMITED (JP) 1993-08-10 US disclosed
EP-0383941-A1 ULTRAVIOLET ABSORBING COSMETIC TEIJIN LIMITED (JP) 1990-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252941-A1 BISBENZOXAZINONE COMPOUND RPS4Y1, RPS4X, H1-4 DHODH 2402/4885MEN1 4533/4885KMT2A 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.